Sandoz Group Ltd Sponsored ADR stock analysis
Want to see SDZNY full AI Analyst Report?
Sandoz Group Ltd Sponsored ADR (SDZNY) Stock Price & Analysis
SDZNY Stock Chart & Stats
- Day’s Range
- $104.10 - $104.10
- 52-Week Range
- $66.13 - $104.10
- Previous Close
- $102.36
- Volume
- N/A
- Average Volume (3M)
- 2,329
- Market Cap
- $44.88B
- Enterprise Value
- $44.69B
- Total Cash (Recent Filing)
- $1.25B
- Total Debt (Recent Filing)
- $6.20B
- Price to Earnings (P/E)
- 69.8
- Beta
- 0.73
- Next Earnings
- Feb 17, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Apr 14, 2026
- Dividend Yield
- 0.98%
Bulls Say, Bears Say
Bulls Say
Biosimilar Growth And Pipeline
Strong biosimilar growth and a broad 36-asset pipeline increase Sandoz’s exposure to higher-growth products and future launches. This expanding platform can support sustained revenue development, diversify the portfolio, and reinforce the company’s position in biologic medicines over multiple years.
Margin And Earnings Expansion
Improving EBITDA, margins, and earnings indicate that the recent recovery is supported by operational progress rather than revenue growth alone. Higher profitability provides additional resources for research, launches, and capacity investment while strengthening earnings resilience across the portfolio.
Liquidity And Leverage
A manageable 1.4x net debt-to-core EBITDA ratio, substantial liquidity, and investment-grade ratings give Sandoz financial flexibility. This supports continued biosimilar investment and helps the company absorb elevated capital spending without placing excessive strain on its balance sheet.
Bears Say
Pricing Erosion
The higher expected pricing decline directly threatens revenue quality and can offset volume gains, particularly in competitive generics and biosimilars. Persistent erosion would pressure gross margins and require continued launches, productivity gains, or mix improvement to protect profitability.
Uneven Revenue Performance
Uneven revenue performance reduces confidence that recent earnings improvement will translate into consistently compounding growth. Generics headwinds and portfolio or market dynamics may create periods of weaker sales, making sustained margin expansion more dependent on execution and new product launches.
Legal And One-Off Costs
Elevated one-off and settlement-related costs can absorb cash that would otherwise support investment, shareholder returns, or debt reduction. Although some payments are spread over time, the scale of these obligations creates a continuing drag on near-term cash generation and reported earnings.
Sandoz Group Ltd Sponsored ADR News
SDZNY FAQ
What was Sandoz Group Ltd Sponsored ADR’s price range in the past 12 months?
What is Sandoz Group Ltd Sponsored ADR’s market cap?
When is Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date?
How were Sandoz Group Ltd Sponsored ADR’s earnings last quarter?
Is Sandoz Group Ltd Sponsored ADR overvalued?
Does Sandoz Group Ltd Sponsored ADR pay dividends?
What is Sandoz Group Ltd Sponsored ADR’s EPS estimate?
How many shares outstanding does Sandoz Group Ltd Sponsored ADR have?
What happened to Sandoz Group Ltd Sponsored ADR’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sandoz Group Ltd Sponsored ADR?
What is the TipRanks Smart Score and how is it calculated?
Sandoz Group Ltd Sponsored ADR Stock Smart Score
Company Description
Sandoz Group Ltd Sponsored ADR
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Richard Saynor
- Employees
- 23,000
- Website
- www.sandoz.com
- Address
- Centralbahnstrasse 4, Basel, ZG, 4051, CH
Sandoz Group Ltd Sponsored ADR (SDZNY) Earnings & Revenues
SDZNY Company Deck
SDZNY Earnings Call
Earnings Call SentimentPositive
The call presented a broadly positive performance story: strong biosimilar-led top-line growth, margin expansion, resilient cash generation despite a significant CapEx cycle, an enlarged 36-asset biosimilar pipeline, major product launches with leading market shares, and strategic investments (Ljubljana center) that support medium-term growth. Near-term challenges include increased pricing erosion (now expected mid-single-digit), temporary generics headwinds (notably in Q1 and in some international markets), short-term tender/pricing disruption in Germany, elevated one-off and settlement-related cash outflows, and a heavier CapEx profile in 2026. Management reaffirmed 2026 guidance and emphasized confidence in 2027–2028 growth driven by upcoming launches and the multisource GLP-1 strategy. On balance, the positives around revenue momentum, profitability improvement, pipeline breadth, and strong commercial execution outweigh the near-term operational and pricing headwinds.
View all SDZNY earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 5 | 2 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 12 | 0 | 0 |













